Get the Stockscreener App
0.3865
5.73%
-0.0235
Glycomimetics Inc stock is traded at $0.3865, with a volume of 1.06M.
It is down -5.73% in the last 24 hours and up +141.86% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.41
Open:
$0.4161
24h Volume:
1.06M
Relative Volume:
0.06
Market Cap:
$26.44M
Revenue:
$1.16M
Net Income/Loss:
$-37.28M
P/E Ratio:
-0.5946
EPS:
-0.65
Net Cash Flow:
$-33.81M
1W Performance:
-21.12%
1M Performance:
+141.86%
6M Performance:
-78.88%
1Y Performance:
-71.37%
1-Day Range:
$0.3832
$0.4161
1-Week Range:
$0.3101
$0.536
52-Week Range:
$0.1406
$3.5299
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle
GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World
GlycoMimetics To Acquire Crescent Biopharma - FinSMEs
GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter
GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance
GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results - Benzinga
GlycoMimetics Stock Triples To Become Top Gainer On Crescent Biopharma Merger Deal: Retail Goes Wild - Barchart
GlycoMimetics Shares Are Soaring Tuesday: Here's Why - Benzinga
Crescent Inks Oncology Merger With $200M In Private Funding - Law360
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
GlycoMimetics Agrees to Acquire Crescent Biopharma - MarketWatch
Crescent rolls up to Glycomimetics merger, $200M in new bread - BioWorld Online
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - Marketscreener.com
US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program - Fierce Biotech
GlycoMimetics enters acquisition agreement with Crescent Biopharma - MSN
Rockville biotech GlycoMimetics to be acquired - Washington Business Journal
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders - Business Wire
GlycoMimetics skyrockets on buyout deal - MSN
GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma - MarketWatch
Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal - MarketWatch
GlycoMimetics to acquire Crescent Biopharma in a strategic merger - Investing.com
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - StockTitan
S&P 500 Energy [Sector] (SREN) QuotePress Release - The Globe and Mail
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Analytical Lens: Exploring GlycoMimetics Inc (GLYC)’s Financial Story Through Ratios - The Dwinnex
TD Cowen downgrades GlycoMimetics Inc (GLYC) rating to a Hold - Knox Daily
Renaissance Technologies LLC Buys 685,151 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
10% Owner Invus Public Equities, L.P. sale 260,873 shares of GlycoMimetics Inc [GLYC] - Knox Daily
GLYC Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Fitness Check: Examining GlycoMimetics Inc (GLYC)’s Key Ratios - The Dwinnex
GlycoMimetics stock plunges to 52-week low of $0.14 - Investing.com
GlycoMimetics stock plunges to 52-week low of $0.14 By Investing.com - Investing.com South Africa
Balance Sheet Insights: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
GlycoMimetics Inc [GLYC] Records 50-Day SMA of $0.1817 - Knox Daily
Understanding GlycoMimetics Inc Inc. (GLYC) Price Performance Through Chart Patterns - The InvestChronicle
GLYC’s valuation metrics: A comprehensive analysis - US Post News
GlycoMimetics GAAP EPS of -$0.17 in-line - MSN
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Glycomimetics Inc Stock (GLYC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):